Khurana, Surender

Antibiotics-Driven Gut Microbiome Perturbation Alters Immunity to Vaccines in Humans

Hagan, T., Cortese, M., Rouphael, N., Boudreau, C., Linde, C., Maddur, M. S., Das, J., Wang, H., Guthmiller, J., Zheng, N.-Y., et al. (2019) · Cell

Gut microbiota and healthImmune responses and vaccinations

Cited by 572

Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses

Saunders, K. O., Lee, E., Parks, R., Martinez, D. R., Li, D., Chen, H., Edwards, R. J., Gobeil, S., Barr, M., Mansouri, K., et al. (2021) · Nature

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies

Cited by 253

Repeat vaccination reduces antibody affinity maturation across different influenza vaccine platforms in humans

Khurana, S., Hahn, M., Coyle, E. M., King, L. R., Lin, T.-L., Treanor, J., Sant, A., & Golding, H. (2019) · Nature Communications

Influenza Virus Research Studiesvaccines and immunoinformatics approaches

Cited by 101

AID Activity in B Cells Strongly Correlates with Polyclonal Antibody Affinity Maturation in-vivo Following Pandemic 2009-H1N1 Vaccination in Humans

Khurana, S., Frasca, D., Blomberg, B., & Golding, H. (2012) · PLoS Pathogens

Influenza Virus Research StudiesT-cell and B-cell Immunology

Cited by 85

What Is the Predictive Value of Animal Models for Vaccine Efficacy in Humans?: The Importance of Bridging Studies and Species-Independent Correlates of Protection

Golding, H., Khurana, S., & Zaitseva, M. (2018) · Cold Spring Harbor Perspectives in Biology

Animal testing and alternativesSARS-CoV-2 and COVID-19 Research

Cited by 67

Licensed H5N1 vaccines generate cross-neutralizing antibodies against highly pathogenic H5N1 clade 2.3.4.4b influenza virus

Khurana, S., King, L. R., Manischewitz, J., Posadas, O., Mishra, A. K., Liu, D., Beigel, J. H., Rappuoli, R., Tsang, J. S., & Golding, H. (2024) · Nature Medicine

Influenza Virus Research StudiesVirology and Viral Diseases

Cited by 57